A Novel Bio-Psychosocial-Behavioral Treatment Model of Panic Disorder

키워드

참고문헌 (126)

1. de Jonge P, "Cross-national epidemiology of panic disorder and panic attacks in the World Mental Health Surveys", Depress Anxiety, 33, pp.1155~1177 (2016)
2. Roy-Byrne PP, "Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairments, course and help-seeking", Br J Psychiatry, 176, pp.229~235 (2000)
3. Lepine JP, "Epidemiology, burden, and disability in depression and anxiety", J Clin Psychiatry, 62(Suppl 13), pp.4~10 (2001)
4. Lepine JP, "The epidemiology of anxiety disorders: prevalence and societal costs", J Clin Psychiatry, 63(Suppl 14), pp.4~8 (2002)
5. Collins PY, "Scientific Advisory Board and the Executive Committee of the Grand Challenges on Global Mental Health. Grand challenges in global mental health", Nature, 475, pp.27~30 (2011)
6. Collins PY, "Grand Challenges in Global Mental Health : integration in research, policy and practice", PLoS Med, 10, pp.e1001434~ (2013)
7. Chen MH, "Treatment-resistant panic disorder : clinical significance, concept and management", Prog Neuropsychopharmacol Biol Psychiatry, 70, pp.219~226 (2016)
8. American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders" (1994), American Psychiatric Association
9. American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders" (2013), American Psychiatric Association
10. Abbar M, "Panic disorder and panic attack", Encephale, 22(5), pp.13~18 (1996)
11. Craske MG, "Panic disorder : a review of DSM-IV panic disorder and proposals for DSM-V", Depress Anxiety, 27, pp.93~112 (2010)
12. Asmundson GJG, "Panic disorder and agoraphobia : an overview and commentary on DSM-5 changes", Depress Anxiety, 31, pp.480~486 (2014)
13. Papakostas YG, "A historical inquiry into the appropriateness of the term “panic disorder”", Hist Psychiatry, 14, pp.195~204 (2003)
14. Hamm AO, "Panic disorder with agoraphobia from a behavioral neuroscience perspective : applying the research principles formulated by the Research Domain Criteria(RDoC)initiative", Psychophysiology, 53, pp.312~322 (2016)
15. Gorman JM, "A neuroanatomical hypothesis for panic disorder", Am J Psychiatry, 146, pp.148~161 (1989)
16. Gorman JM, "Neuroanatomical hypothesis of panic disorder, revised", Am J Psychiatry, 157, pp.493~505 (2000)
17. Santos M, "From neural to genetic substrates of panic disorder : insights from human and mouse studies", Eur J Pharmacol, 759, pp.127~141 (2015)
18. Dresler T, "Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder", J Neural Transm(Vienna), 120, pp.3~29 (2013)
19. Henningsen P, "Still modern? Developing the biopsychosocial model for the 21st century", J Psychosom Res, 79, pp.362~363 (2015)
20. Benning TB, "Limitations of the biopsychosocial model in psychiatry", Adv Med Educ Pract, 6, pp.347~352 (2015)
21. Davies W, "Reassessing biopsychosocial psychiatry", Br J Psychiatry, 210, pp.3~5 (2017)
22. Roy-Byrne PP, "Panic disorder in primary care : biopsychosocial differences between recognized and unrecognized patients", Gen Hosp Psychiatry, 22, pp.405~411 (2000)
23. Schumacher J, "The genetics of panic disorder", J Med Genet, 48, pp.361~368 (2011)
24. Jacob C, "Genetics of panic disorder : focus on association studies and therapeutic perspectives", Expert Rev Neurother, 10, pp.1273~1284 (2010)
25. Dai JX, "Enhanced contexutal fear memory in central serotonin-deficient mice", Proc Natl Acad Sci U S A, 105, pp.11981~11986 (2008)
26. Uchida RR, "Decreased left temporal lobe volume of panic patients measured by magnetic resonance imaging", Braz J Med Biol Res, 36, pp.925~929 (2003)
27. Klemenhagen KC, "Increased fear response to contextual cues in mice lacking the 5-HT1A receptor", Neuropsychopharmacology, 31, pp.101~111 (2006)
28. McDevitt RA, "Regulation of dorsal raphe nucleus function by serotonin autoreceptors : a behavioral perspective", J Chem Neuroanat, 41, pp.234~246 (2011)
29. Neumeister A, "Reduced serotonin type 1A receptor binding in panic disorder", J Neurosci, 24, pp.580~591 (2004)
30. Muller JM, "Serotonin transporter deficient mice are vulnerable to escape deficits following inescapable shocks", Genes Brain Behav, 10, pp.166~175 (2011)
31. Wellman CL, "Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice", J Neurosci, 27, pp.684~691 (2007)
32. Milad MR, "Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder", Biol Psychiatry, 66, pp.1075~1082 (2009)
33. Likhtik E, "Prefrontal cortex of the amygdala", J Neurosci, 25, pp.7429~7437 (2005)
34. Beique JC, "Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex", Proc Natl Acad Sci U S A, 104, pp.9870~9875 (2007)
35. Savelieva KV, "Genetic disruption of both tryptophan hydroxylase genes dramatically reduces serotonin and affects behavior in models sensitive to antidepressants", PLoS One, 3, pp.e3301~ (2008)
36. Weisstaub NV, "Cortical 5-HT21 receptor signaling modulates anxiety-like behaviors in mice", Science, 313, pp.536~540 (2006)
37. Allen YS, "Neuropeptide Y distribution in the rat brain", Science, 221, pp.877~879 (1983)
38. Chronwall BM, "The anatomy of neuropeptide-Y-containing neurons in rat brain", Neuroscience, 15, pp.1159~1181 (1985)
39. Browers ME, "Neuropeptide regulation of fear and anxiety : implications of cholecytokinin, endogenous opioids, and neuropeptide Y", Physiol Behav, 107, pp.699~710 (2012)
40. Verma D, "NPY controls fear conditioning and fear extinction by combined action on Y(1)and Y(2)receptors", Br J Pharmacol, 166, pp.1461~1473 (2012)
41. Domschke K, "Chromosome 4q31-34 panic disorder risk locus: association of neuropeptide Y Y5 receptor variants", Am J Med Gent B: Neuropsychiatr Genet, 147B, pp.510~516 (2008)
42. Kamichi S, "Immunohistochemical localization of gastrin-releasing peptide receptor in the mouse brain", Brain Res, 1032, pp.162~170 (2005)
43. Wada E, "Neuromedin B and gatrin-releasing peptide mRNAs are differentially distributed in the rat of nervous system", J Neurosci, 10, pp.2917~2930 (1990)
44. Chaperon F, "Gastrin-releasing peptide signaling plays a limited and subtle role in amygdala physiology and aversive memory", PLoS One, 7, pp.e34963~ (2012)
45. Shumyatsky GP, "Identification of a signaling networks in lateral nucleus of amygdala important for inhibiting memory specifically related to learned fear", Cell, 111, pp.905~918 (2002)
46. Gaier ED, "Haploinsufficiency in peptidylglycine alpha-amidating monooxygenase leads to altered synaptic transmission in the amygdala and impaired emotional responses", J Neurosci, 30, pp.13656~13669 (2010)
47. Risbrough VB, "CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues", Neuropsychopharmacology, 34, pp.1494~1503 (2009)
48. Keck ME, "Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case", control study for panic disorder, 2008, pp.147B, 1196~1204
49. Smaller JW, "The corticotrophin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder", Biol Psychiatry, 57, pp.1485~1492 (2005)
50. Frielingsdorf H, "Variant brain-derived neurotrophic factor Val66Met endophenotypes : implications for posttraumatic stress disorder", Ann N Y Acad Sci, 1208, pp.150~157 (2010)
51. Soliman F, "A genetic variant BDNF polymorphism alters extinction learning in both mouse and human", Science, 327, pp.863~866 (2010)
52. Liu IY, "Brain-derived neurotrophic factor plays a criticl role in contextual fear conditioning", J Neurosci, 24, pp.7958~7963 (2004)
53. Otnaess MK, "Evidence for a possible association of neurotrophin receptor(NTRK-3)gene polymorphisms with hippocampal function and schizophrenia", Neurobiol Dis, 34, pp.518~524 (2009)
54. Takahashi H, "Postsynaptic TrkC and presynaptic PTPsigma function as a bidirectional excitatory synaptic organizing complex", Neuron, 69, pp.287~303 (2011)
55. Sahun I, "Dissociation between CA3-CA1 synaptic plasticity and associative learning in TgNTRK3 transgenic mice", J Neurosci, 27, pp.2253~2260 (2007)
56. Freire RC, "Current pharmacological interventions in panic disorder", CNS Neurol Disord Drug Targets, 13, pp.1057~1065 (2014)
57. Generalised Anxiety Disorder and Panic Disorder (with and without Agoraphobia) in Adults: Management in Primary, Secondary and Community Care, "National Collaborating Centre for Mental Health", National Institute for Health and Clinical Excellence (NICE), ~ (2011)
58. Ferguson JM, "Relapse prevention of panic disorder in adult outpatients responders to treatment with venlafaxine extend release", J Clin Psychiatry, 68, pp.58~68 (2007)
59. Pollack MH, "A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder", Depress Anxiety, 24, pp.1~14 (2007)
60. Sheehan DV, "Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder", J Clin Psychiatry, 66, pp.34~40 (2005)
61. American Psychiatric Association, "Practice Guideline for the Treatment of Patients with Panic Disorder" (2009), American Psychiatric Publishing Inc
62. Bandelow B, "Obsessive-Compulsive and Post-Traumatic Stress Disorder World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorder-first revision", World J Biol Psychiatry, 9, pp.248~312 (2008)
63. Perna G, "Novel investigational therapeutics for panic disorder", Expert Opin Investig Drug, 24, pp.491~505 (2015)
64. Johnson PL, "An animal model of panic vulnerability with chronic disinhibition of the dorsomedial", perifornical hypothalamus, 2012, pp.107, 686~698
65. Johnson PL, "Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats", J Psychopharmacol, 27, pp.152~161 (2013)
66. Shekhar A, "LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats", Neuropharmacology, 39, pp.1139~1146 (2000)
67. Schoepp DD, "LY354740, an mGlu2", 3 receptor agonist as a novel approach to treat anxiety, Stress, pp.2003, 6[DOI]
68. Bergink W, "Metabotropic glutamate II receptor agonists in panic disorder : a double blind clinical trial with LY354740", Int Clin Psychopharmacl, 20, pp.291~293 (2005)
69. Kellner M, "Effects of a metabotropic glutamate(2", 3) receptor agonist (LY544344, Psychopharmacology (Berl), pp.2005, 179[DOI]
70. Johnson PL, "Panic-prone state induced in rats with GABA dysfunction in the dorsomedial hypothalamus is mediated by NMDA receptors", J Neurosci, 26, pp.7093~7104 (2006)
71. Johnson PL, "A key role for orexin in panic anxiety", Nat Med, 16, pp.111~115 (2010)
72. Johnson PL, "Orexin, stress, and anxiety", panic states, 2012, pp.198, 133~161
73. Johnson PL, "Activation of the orexin 1 receptor is a critical component of CO2-mediated anxiety and hypertension but not bradycardia", Neuropsychopharmacology, 37, pp.1911~1922 (2012)
74. Sergio Tde O, "Effects of dorsal periaqueductal gray CRF1- and CRF2- receptor stimulation in animal models of panic", Psychoneuroendocrinology, 49, pp.321~330 (2014)
75. Shekhar A, "A selective, non-peptide CRF receptor 1 antagonist prevents sodium lactate-induced acute panic-like responses", Int J Neuropsychopharmacol, 14, pp.355~365 (2011)
76. Bailey JE, "Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317574 in the 7.5% CO2 proof-of-concept experimental model of human anxiety", J Psychopharmacol, 25, pp.1199~1206 (2011)
77. Johnson PL, "Neural pathways underlying lactate-induced panic", Neuropsychopharmacology, 33, pp.2093~2107 (2008)
78. Shekhar A, "Angiotensin-II is a putative neurotransmitter in lactate-induced panic-like responses in rats with disruption of GABAergic inhibition in the dorsomedial hypothalamus", J Neurosci, 26, pp.9205~9215 (2006)
79. Casarotto PC, "Opposing roles for cannabinoid receptor type-1(CB(1))and transient receptor potential vanilloid type-1 channel(TRPV1)on the modulation of panic-like responses in rats", Neuropsychopharmacology, 37, pp.478~486 (2012)
80. Micale V, "Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels", Neuropsychopharmacology, 34, pp.593~606 (2009)
81. John CS, "N-arachidonyl-serotonin in the basolateral amygdala increases anxiolytic behavior in the elevated plus maze", Behav Brain Res, 233, pp.382~388 (2012)
82. SPA-RQ, "Biol Psychiatry", 2009, 94~97
83. Iijima M, "Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists : TASP0233278 and TASP0390325", Br J Pharmacol, 171, pp.3511~3525 (2014)
84. Zwanzger P, "Neuronal Network of panic disorder : the role of the neuropeptide cholecystokinin", Depress Anxiety, 29, pp.762~774 (2012)
85. Asami T, "Sexually dimorphic gray matter volume reduction in patients with panic disorder", Psychiatry Res, 173, pp.128~134 (2009)
86. Hayano F, "Smaller amygdala is associated with anxiety in patients with panic disorder", Psychiatry Clin Neurosci, 63, pp.266~276 (2009)
87. Massana G, "Amygdala atrophy in panic disorder patients detected by volumetric magnetic resonance imaging", Neuroimage, 19, pp.80~90 (2003)
88. Uchida RR, "Decreased left temporal lobe volume of panic patients measured by magnetic resonance imaging", Braz J Med Biol Res, 36, pp.925~929 (2003)
89. Chechko N, "Unstable prefrontal response to emotional conflict and activation of lower limbic structures and brainstem in remitted panic disorder", PLoS One, 4, pp.e5537~ (2009)
90. Pillay SS, "fMRI of fearful facial affect recognition in panic disorder : the cingulate gyrus-amygdala connection", J Affect Disord, 94, pp.173~181 (2006)
91. Pillay SS, "Recognition of happy facial affect in panic disorder : an fMRI study", J Anxiety Disord, 21, pp.381~393 (2007)
92. Protopopescu X, "Increased brainstem volume in panic disorder : a voxel-based morphometric study", Neuroreport, 17, pp.361~363 (2006)
93. Vythilingam M, "Temporal lobe volume in panic disorder : a quantitative magnetic resonance imaging study", Psychiatry Res, 99, pp.75~82 (2000)
94. Boldrini M, "Hippocampal granule neuron number and dentate gyrus volume in antidepressant-treated and untreated major depression", Neuropsychopharmacology, 38, pp.1068~1077 (2013)
95. Warner-Schmidt JL, "Hippocampal neurogenesis : opposing effects of stress and antidepressant treatment", Hippocampus, 16, pp.239~249 (2006)
96. Yucel K, "Bilateral hippocampal volume increase in patients with bipolar disorder and short-term lithium treatment", Neuropsychopharmacology, 33, pp.361~367 (2008)
97. Trzesniak C, "(1)H magnetic resonance spectroscopy imaging of the hippocampus in patients with panic disorder", Psychiatry Res, 182, pp.261~265 (2010)
98. flumazenil positron emission tomography, "Arch Gen Psychiatry", 2008, 1166~1175
99. Uchida RR, "Regional gray matter abnormalies in panic disorder : a voxel-based morphometry study", Psychiatry Res, 163, pp.21~29 (2008)
100. Tuescher O, "Differential activity of subgenual cingulate and brainstem in panic disorder and PTSD", J Anxiety Disord, 25, pp.251~257 (2011)
101. Lissek S, "Impaired discriminative fear-conditioning resulting from elevated fear responding to learned safety cues among individuals with panic disorder", Behav Res Ther, 47, pp.111~118 (2009)
102. Maddock RJ, "Brain regions showing increased activation by threat-related words in panic disorder", Neuroreport, 14, pp.325~328 (2003)
103. Agustin-Pavon C, "Lesions of ventrolateral prefrontal or anterior orbitofrontal cortex in primates heighten negative emotion", Biol Psychiatry, 72, pp.266~272 (2012)
104. Zelinski EL, "Prefrontal cortical contributions during discriminative fear conditioning, extinction, and spontaneous recovery in rats", Exp Brain Res, 203, pp.285~297 (2010)
105. Kent JM, "Prediction of panic response to a respiratory stimulant by reduced orbitofrontal cerebral blood flow in panic disorder", Am J Psychiatry, 162, pp.1379~1381 (2005)
106. Lai CH, "Fronto-temporo-insula gray matter alterations of first-episode, drug-naive, and very late-onset panic disorder", J Affect Disord, 140, pp.285~291 (2012)
107. Roppongi T, "Posterior orbiotofrontal sulcogyral pattern associated with orbitofrontal cortex volume reduction and anxiety trait in panic disorder", Psychiatry Clin Neurosci, 64, pp.318~326 (2010)
108. Critchley HD, "Neuroanatomical basis for first-and second-order representations of bodily states", Nat Neurosci, 4, pp.207~212 (2001)
109. Critchley HD, "Neural systems supporting interoceptive awareness", Nat Neurosci, 7, pp.189~195 (2004)
110. Nagai M, "Insular cortex and neuropsychiatric disorders : a review of recent literature", Eur Psychiatry, 22, pp.387~394 (2007)
111. Yang Y, "The neural correlates of cognitive behavior therapy : recent progress in the investigation of patients with panic disorder", Behav Res Ther, 62, pp.88~96 (2014)
112. Prasko J, "The challenge of regional brain metabolism(18FDG PET)in panic disorder during the treatment with cognitive behavioral therapy or antidepressant", Neuro Endocrinol Lett, 25, pp.340~348 (2004)
113. Sakai Y, "Changes in cerebral glucose utilization in patients with panic disorder treated with cognitive-behavioral therapy", Neuroimage, 33, pp.218~226 (2006)
114. Seo HJ, "Changes in cerebral blood flow after cognitive behavior therapy in patients with panic disorder : a SPECT study", Neuropsychiatr Dis Treat, 10, pp.661~669 (2014)
115. Kircher T, "Effect of cognitive-behavioral therapy on neural correlates of fear conditioning in panic disorder", Biol Psychiatry, 73, pp.93~101 (2013)
116. Straube B, "Neural correlates of procedural variants in cognitive behavioral therapy : a randomized, controlled multicenter fMRI study", Psychother Psychosom, 83, pp.222~233 (2014)
117. Gloster AT, "Mechanism of action in CBT (MAC): methods of a multi-center randomized controlled trial in 369 patients with panic disorder and agoriaphobia", Eur Arch Psychiatry Clin Neurosci, 259(Suppl 2), pp.S155~S166 (2009)
118. Gloster AT, "Psychological treatment for panic disorder with agoraphobia : a randomized controlled trial to examine the role of therapist-guided exposure in situ in CBT", J Consult Clin Psychol, 79, pp.406~420 (2011)
119. Hofmanns SG, "Cognitive processes during fear acquisition and extinction in animals and humans : implications for exposure therapy of anxiety disorders", Clin Psychol Rev, 28, pp.199~210 (2008)
120. McNaughton N, "A two-dimensional neurophysiology of defense : fear", anxiety and defensive distance, 2004, pp.28, 285~305
121. Eley TC, "Therapygenetics : the 5HTTLPR and response to psychological therapy", Mol Psychiatry, 17, pp.236~237 (2012)
122. Reif A, "MAOA and mechanisms of panic disorder revisited : from bench to molecular psychotherapy", Mol Psychiatry, 19, pp.122~128 (2014)
123. Choi KY, "Plasticity-augemented psychotherapy for refractory depressive and anxiety disorders", Prog Neuropsychopharmacol Biol Psychiatry, 70, pp.134~147 (2016)
124. Lang PJ, "Fear and anxiety : animal models and human cognitive cognitive psychophysiology", J Affect Disord, 61, pp.137~159 (2000)
125. Kim EJ, "Dorsal periaqueductal gray-amygdala pathway conveys both innate and learned fear response in rats", Proc Natl Acad Sci U S A, 110, pp.14795~14800 (2013)
126. LeDoux J, "Rethinking the emotional brain", Neuron, 73, pp.653~676 (2012)

관련 논문AI추천